PCSK9 inhibitors

被引：0

作者：

Farnier, Michel ^{[1
]}

机构：

[1] Point Med, Dijon, France

来源：

CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION | 2015年 / 19卷 / 03期

关键词：

PCSK9; LDL-cholesterol; LDL-receptor; Monoclonal antibodies; Hypercholesterolemia; AMG; 145; HYPERCHOLESTEROLEMIA; TRIAL; LDL; EVOLOCUMAB;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PCSK9 is a key regulator of LDL receptor activity. Several anti-PCSK9 therapeutic strategies are being investigated. Monoclonal antibodies are the most advanced and promising strategy with about 60% decrease of LDL-cholesterol. In phase II and III trials, monoclonal antibodies alirocumab and evolocumab appeared safe and well tolerated. Several cardiovascular outcome trials are ongoing to determine the cardiovascular benefit in relation to the lowering effect of atherogenic lipoproteins with PCSK9 inhibitors, and to give more information on the safety of very low levels of LDL-cholesterol.

引用

页码：66 / 70

页数：5

共 15 条

[1] Mutations in PCSK9 cause autosomal dominant hypercholesterolemia [J].

Abifadel, M ;

Varret, M ;

Rabès, JP ;

Allard, D ;

Ouguerram, K ;

Devillers, M ;

Cruaud, C ;

Benjannet, S ;

Wickham, L ;

Erlich, D ;

Derré, A ;

Villéger, L ;

Farnier, M ;

Beucler, I ;

Bruckert, E ;

Chambaz, J ;

Chanu, B ;

Lecerf, JM ;

Luc, G ;

Moulin, P ;

Weissenbach, J ;

Prat, A ;

Krempf, M ;

Junien, C ;

Seidah, NG ;

Boileau, C .

NATURE GENETICS, 2003, 34 (02) :154-156

[2] A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia [J].

Blom, Dirk J. ;

Hala, Tomas ;

Bolognese, Michael ;

Lillestol, Michael J. ;

Toth, Phillip D. ;

Burgess, Lesley ;

Ceska, Richard ;

Roth, Eli ;

Koren, Michael J. ;

Ballantyne, Christie M. ;

Monsalvo, Maria Laura ;

Tsirtsonis, Kate ;

Kim, Jae B. ;

Scott, Rob ;

Wasserman, Scott M. ;

Stein, Evan A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (19) :1809-1819

[3] Low LDL cholesterol in African Americans resulting from frequent nonsense mutations in PCSK9 [J].

Cohen, J ;

Pertsemlidis, A ;

Kotowski, IK ;

Graham, R ;

Garcia, CK ;

Hobbs, HH .

NATURE GENETICS, 2005, 37 (03) :328-328

[4] Sequence variations in PCSK9, low LDL, and protection against coronary heart disease [J].

Cohen, JC ;

Boerwinkle, E ;

Mosley, TH ;

Hobbs, HH .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (12) :1264-1272

[5]

Famier M, 2014, ARCH CARDIOVASC DIS, V107, P58

[6] PCSK9 inhibitors [J].

Farnier, Michel .

CURRENT OPINION IN LIPIDOLOGY, 2013, 24 (03) :251-258

[7] Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial [J].

Fitzgerald, Kevin ;

Frank-Kamenetsky, Maria ;

Shulga-Morskaya, Svetlana ;

Liebow, Abigail ;

Bettencourt, Brian R. ;

Sutherland, Jessica E. ;

Hutabarat, Renta M. ;

Clausen, Valerie A. ;

Karsten, Verena ;

Cehelsky, Jeffrey ;

Nochur, Saraswathy V. ;

Kotelianski, Victor ;

Horton, Jay ;

Mant, Timothy ;

Chiesa, Joseph ;

Ritter, James ;

Munisamy, Malathy ;

Vaishnaw, Akshay K. ;

Gollob, Jared A. ;

Simon, Amy .

LANCET, 2014, 383 (9911) :60-68

[8]

Hedrick JA, 2009, CURR OPIN INVEST DR, V10, P938

[9] Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial [J].

Koren, Michael J. ;

Giugliano, Robert P. ;

Raal, Frederick J. ;

Sullivan, David ;

Bolognese, Michael ;

Langslet, Gisle ;

Civeira, Fernando ;

Somaratne, Ransi ;

Nelson, Patric ;

Liu, Thomas ;

Scott, Rob ;

Wasserman, Scott M. ;

Sabatine, Marc S. .

CIRCULATION, 2014, 129 (02) :234-243

[10] PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges [J].

Norata, Giuseppe Danilo ;

Tibolla, Gianpaolo ;

Catapano, Alberico Luigi .

VASCULAR PHARMACOLOGY, 2014, 62 (02) :103-111

← 1 2 →